d-beta-hydroxybutrate

Phase 1Small molecule

UUniversity of Southern California

d-beta-hydroxybutrate is one of 30 small molecule programs targeting Physical Activity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Physical ActivityActive, not recruiting

Physical ActivityPhase 1

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Physical Activity

#DrugCompanyPhaseTrials

Xolair

Roche

Approved

1 2

Hemlibra

Roche

Approved

1 3

Ranexa

MMenarini International Operations Luxembourg SA

Approved

1 4

Tnkase

Roche

Phase 3

1 5

Zometa

Pfizer

Phase 3

1 6

Activase

Roche

Phase 3

1 7

Striverdi Respimat

Boehringer Ingelheim

Phase 3

1 8

Spiriva

Boehringer Ingelheim

Phase 3

1 9

Aclidinium/formoterol

AstraZeneca

Approved

1 10

Farxiga

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Physical Activity

NCT07218497

Clinical

Trials by Indication[1]

Physical Activity1 trial

Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism

Not yet recruiting·UUniversity of Southern California·Phase 1·NCT07218497·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for d-beta-hydroxybutrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — d-beta-hydroxybutrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for d-beta-hydroxybutrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Southern California

d-beta-hydroxybutrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Physical Activity1 trial

References

Drug Info

Quick Facts

Related News